HE4、CA125联合检测对卵巢恶性肿瘤的临床诊断价值

Clinical diagnostic value of combined detection of HE4, CA125 inmalignant ovarian tumor

目的探讨人附睾蛋白4(human epididymis protein4,HE4)和CA125联合检测对卵巢癌的诊断价值。方法采用化学发光法检测46例卵巢癌患者(卵巢癌组)、43例卵巢良性肿瘤患者(卵巢良性肿瘤组)及46例体检健康者(对照组)血清HE4水平,并与CA125试剂盒检测结果进行比较分析。结果卵巢癌组血清HE4水平(275.45±319.77)pmol/L明显高于卵巢良性肿瘤组(47.35±20.32)pmol/L和对照组(41.7±7.2)pmol/L,差异均有统计学意义(P<0.01);HE4诊断卵巢癌较CA125有更高特异性,联合检测与单项指标检测方式进行比较敏感性及特异性差异有统计学意义(P<0.01)。结论 HE4联合CA125在诊断卵巢癌具有较高诊断价值。

Objective To explore the human epididymis protein 4（human epididymis protein4, HE4） and CA125 combined detection in diagnosis of ovarian cancer. Methods Using chemiluminescence in 46 patients with ovarian carcinoma（ovarian cancer group）,43 cases of benign ovarian tumor（benign ovarian tumor group） and 46 cases of healthy persons（control group） the levels of serum HE4, and the results were compared with CA125 kit. Results The serum HE4 level in ovarian cancer group（275.45±319.77） pmol/L was significantly higher than that in benign ovarian tumor group（47.35±20.32） pmol/L and control group（41.7±7.2） pmol/L, the differences were statistically significant（P〈0.01）; HE4 diagnosis of ovarian cancer than CA125 has higher specificity, joint detection and detection methods of single index comparison of the sensitivity and specificity of the difference was statistically significant（P〈0.01）, Conclusion HE4 combined with CA125 has higher diagnostic value in the diagnosis of ovarian cancer